11-05-2014, 12:45 PM
JNJ's competition should trail far behind. I think the reason GILD isn't expensive is because of fear that the premium price tag for their Hep C drugs won't stand. Of course their case is that their customers are not patients, but insurance companies, and they're saving their customers a ton of money.
I looked at it long enough to decide it was a buy, and got in at an average cost basis of 100.
I looked at it long enough to decide it was a buy, and got in at an average cost basis of 100.